Comparison · NCT05780437-fb2ce013
AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants With a Safety Outcome Through Day 5
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AZD7442 Plus SOC vs Placebo Plus SOC: Number of Participants With a Safety Outcome Through Day 5. Trial comparisons, record NCT05780437-fb2ce013. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05780437-fb2ce013
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.255 | 0.224 | 0.288 | wilson | |
| Risk in group 2 | 0.286 | 0.254 | 0.32 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0308 | -0.0769 | 0.0155 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.892 | 0.752 | 1.06 | log | |
| Odds ratio, group 1 over group 2 | 0.855 | 0.676 | 1.08 | log | |
| Number needed to treat, for one fewer participant with the outcome on AZD7442 Plus SOC than on Placebo Plus SOC | 32.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AZD7442 Plus SOC | * AZD7442 600 mg solution (4 separate vials, 2 containing 150 mg each of AZD88995 and 2 containing 150 mg each of AZD1061); administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion~AZD7442: AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct epitopes on the receptor-binding domain of the spike protein of SARS-CoV- 2.~Remdesivir: Antiviral agent | 181 | 710 | OG000 |
| Group 2 | Placebo Plus SOC | * Placebo administered by IV infusion~* Remdesivir is provided to all study participants as SOC unless contraindicated for an individual patient; administered by IV infusion~Placebo: Commercially available 0.9% sodium chloride solution~Remdesivir: Antiviral agent | 202 | 707 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With a Safety Outcome Through Day 5
- Description
Safety outcomes are defined as Death, SAE, clinical organ failure, serious infections, or Grade 3 or 4 event through Day 5. Seriousness was based on the definition of the term at 21CFR312.32~AEs were graded for severity by the treating investigator, according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (also known at the DAIDS AE Grading Table), U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. \[July 2017\]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf). The following generic grading descriptions from the DAIDS AE Grading Table are provided for context: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening
- Time frame
- Through Day 5
- Population
Source ClinicalTrials.gov
Trial
- Title
- AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- NCT number
- NCT05780437
- Phases
- PHASE3
- Conditions
- COVID-19
- Interventions
- AZD7442, Placebo, Remdesivir
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2024-07-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05780437?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05780437-fb2ce013